Epidermal growth-factor-induced transcript isoform variation drives mammary cell migration

PLoS One. 2013 Dec 6;8(12):e80566. doi: 10.1371/journal.pone.0080566. eCollection 2013.

Abstract

Signal-induced transcript isoform variation (TIV) includes alternative promoter usage as well as alternative splicing and alternative polyadenylation of mRNA. To assess the phenotypic relevance of signal-induced TIV, we employed exon arrays and breast epithelial cells, which migrate in response to the epidermal growth factor (EGF). We show that EGF rapidly--within one hour--induces widespread TIV in a significant fraction of the transcriptome. Importantly, TIV characterizes many genes that display no differential expression upon stimulus. In addition, similar EGF-dependent changes are shared by a panel of mammary cell lines. A functional screen, which utilized isoform-specific siRNA oligonucleotides, indicated that several isoforms play essential, non-redundant roles in EGF-induced mammary cell migration. Taken together, our findings highlight the importance of TIV in the rapid evolvement of a phenotypic response to extracellular signals.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alternative Splicing
  • Cell Line
  • Cell Movement / drug effects
  • Epidermal Growth Factor / pharmacology*
  • Epithelial Cells / cytology
  • Epithelial Cells / drug effects*
  • Epithelial Cells / metabolism
  • Exons*
  • Female
  • Genetic Variation*
  • Humans
  • Mammary Glands, Human / cytology
  • Mammary Glands, Human / drug effects
  • Mammary Glands, Human / metabolism
  • Oligonucleotide Array Sequence Analysis
  • Polyadenylation
  • RNA, Messenger / antagonists & inhibitors
  • RNA, Messenger / genetics*
  • RNA, Messenger / metabolism
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Signal Transduction
  • Transcriptome*

Substances

  • RNA, Messenger
  • RNA, Small Interfering
  • Epidermal Growth Factor

Grants and funding

The authors' research is supported by the German-Israeli Project Cooperation (DIP), the National Cancer Institute (Bethesda, MD), the European Research Council, the Seventh Framework Program of the European Commission, the Israel Cancer Research Fund and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Israel Science Foundation (ISF) and the Leir Charitable Foundation. WJK is supported by a Ph.D. Track fellowship for specialist medical doctors donated by the Linda and Michael Jacobs Charitable Trust. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair and ED is the incumbent of the Henry J. Leir Professorial Chair. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.